Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Steven Sun"'
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Autor:
Hervé Avet-Loiseau, Steven Sun, Torben Plesner, Andrew Spencer, Aurore Perrot, Thierry Facon, Rachel Kobos, Philippe Moreau, Saad Z. Usmani, Meletios A. Dimopoulos, Shinsuke Iida, Jianping Wang, Maria Krevvata, Niels W.C.J. van de Donk, Vania Hungria, Maria-Victoria Mateos, Katja Weisel, Bruno Paiva, Nizar J. Bahlis, Michele Cavo, Christoph Heuck, Nikhil C. Munshi, Jesús F. San-Miguel, Shaji Kumar, M. Qi, Pieter Sonneveld, Jon Ukropec
Publikováno v:
Cavo, M, San-Miguel, J, Usmani, S Z, Weisel, K, Dimopoulos, M A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V, Moreau, P, Mateos, M-V, Perrot, A, Iida, S, Facon, T, Kumar, S, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
Blood, 139(6), 835-844. American Society of Hematology
Cavo, M, San-Miguel, J F F, Usmani, S Z, Weisel, K C, Dimopoulos, M A A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V T D M, Moreau, P, Mateos, M V, Perrot, A, Iida, S, Facon, T, Kumar, S K, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N C 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
Blood, 139(6), 835-844. American Society of Hematology
Cavo, M, San-Miguel, J F F, Usmani, S Z, Weisel, K C, Dimopoulos, M A A, Avet-Loiseau, H, Paiva, B, Bahlis, N J, Plesner, T, Hungria, V T D M, Moreau, P, Mateos, M V, Perrot, A, Iida, S, Facon, T, Kumar, S K, van de Donk, N W C J, Sonneveld, P, Spencer, A, Krevvata, M, Heuck, C, Wang, J, Ukropec, J, Kobos, R, Sun, S, Qi, M & Munshi, N C 2022, ' Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA ', Blood, vol. 139, no. 6, pp. 835-844 . https://doi.org/10.1182/blood.2021011101
We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c64997dd452605ab785f5859d6df78
https://research.vumc.nl/en/publications/4fe089e5-72a4-42e8-a3c4-bb08bb52d9fe
https://research.vumc.nl/en/publications/4fe089e5-72a4-42e8-a3c4-bb08bb52d9fe
Autor:
Nikki A. Deangelis, Shaji Kumar, M. Qi, Thierry Facon, Hervé Avet-Loiseau, Steven Sun, Jesús F. San-Miguel, Rachel Kobos, Hang Quach, Maria Krevvata, Christoph Heuck, Saad Z. Usmani, Rian Van Rampelbergh, Michele Cavo, Anupa Kudva, Bruno Paiva, Huiling Pei, Andrzej Jakubowiak, Ming Qi, Maria-Victoria Mateos, Jon Ukropec, Cyrille Touzeau, Jianping Wang, Priya Ramaswami, Gordon Cook, Meletios A. Dimopoulos, Nizar J. Bahlis
Publikováno v:
Blood. 139(4)
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/mel
Autor:
Xiaoyan Ke, Angela Howes, Mariya Salman, Lugui Qiu, Jianyong Li, Jie Jin, Xiao-Jun Huang, Daobin Zhou, Hanyun Ren, Ming Hou, Yu Hu, Yingmin Liang, Peng Wu, Junmin Li, Chunting Zhao, Yue Lv, Jingzhao Wang, Steven Sun, Jianda Hu, Jianmin Wang, Aining Sun, Ting Liu, Xiequn Chen
Publikováno v:
Cancer Medicine
In the Asia‐Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Rituximab is widely used in this setting when purine analog‐based therapies are n
Autor:
Steven Sun, Mats Jerkeman, Simon Rule, Georg Hess, John Bothos, Isabelle Bence-Bruckler, Mathias Witzens-Harig, Nibedita Bandyopadhyay, Fritz Offner, Christopher Enny, Jessica Vermeulen, Dolores Caballero, Aleksandra Rizo, Shana Traina, Sriram Balasubramanian, Chiara Rusconi, Martin Dreyling, Cristina João, Seok-Goo Cho, Rodrigo Santucci Silva, Jenna D. Goldberg, Marek Trneny, Wojciech Jurczak
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97f3968cb14298604d326493927a7acf
https://ruj.uj.edu.pl/xmlui/handle/item/117399
https://ruj.uj.edu.pl/xmlui/handle/item/117399
Publikováno v:
Clinical Journal of the American Society of Nephrology. 5:598-606
Background and objectives: Extended-interval dosing of epoetin alfa (EPO) is commonly used to treat anemia in patients with chronic kidney disease (CKD). This study aimed to demonstrate that EPO dosed every 2 weeks (Q2W) and every 4 weeks (Q4W) was n
Autor:
David H. Henry, Wayne Rackoff, Steven Sun, Margaret Tonda, Timothy P Cooley, Martin O'Connell
Publikováno v:
The Oncologist. 12:114-123
Despite a decreased incidence of AIDS-related Kaposi's sarcoma (KS) due to the advent of highly active antiretroviral therapy, approximately 15% of AIDS patients still develop AIDS-related KS. This study evaluated the clinical benefit, tumor response
Publikováno v:
The Oncologist. 12:72-78
Purpose. To examine early changes in CA125 relative to objective response in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD) or topotecan and to compare the CA125 trends between the two chemotherapeutics. Pat
Autor:
Alberto Notarbartolo, Lorenzo Melani, Enrico P. Veltri, Philip T. Sager, Ramachandran Suresh, Christie M. Ballantyne, Alexandre LeBeaut, Steven Sun, Leslie Lipka, John Houri
Publikováno v:
Circulation. 107:2409-2415
Background— Despite the established efficacy of statins, many patients do not achieve recommended LDL cholesterol (LDL-C) goals. Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and incre